26258 Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Instrument type No. of 

respondents 

No. of 

responses per 

respondent 

Average 

burden per 

respondent 

(in hours) 

Eligible participants ......................................... Baseline questionnaire ................................... 40 1 20/60 

Symptom survey ............................................ 40 5 2/60 

Scripted commute data collection .................. 40 2 2 

Dated: May 5, 2010. 

Maryam I. Daneshvar, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2010–11180 Filed 5–10–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director; Notice of Charter 

Renewal for the National Science 

Advisory Board for Biosecurity 

In accordance with Title 41 of the 

U.S. Code of Federal Regulations, 

Section 102–3.65(a), notice is hereby 

given that the Charter for the National 

Science Advisory Board for Biosecurity 

(NSABB) was renewed for an additional 

two-year period on April 7, 2010. 

It is determined that NSABB is in the 

public interest in connection with the 

performance of duties imposed on the 

Department of Health and Human 

Services by law, and that these duties 

can best be performed through the 

advice and counsel of this group. 

Inquiries may be directed to Jennifer 

Spaeth, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or spaethj@od.nih.gov. 

Dated: May 4, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–11043 Filed 5–10–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Erythroid Progenitor Cell Line for 

Hematological Disease Applications 

Description of Invention: Plasmodium 

vivax (malaria) is a significant health 

concern in many parts of Asia, Latin 

America, North Africa, and the Middle 

East. There is a lack of continuous 

culture systems for this pathogen. The 

subject technology is an erythroid 

progenitor continuous cell line (termed 

CD36E) identified by erythroid markers 

CD36, CD33, CD44, CD71, CD235, and 

globoside. These CD36E cells are 

heterozygous for Fya and Fyb (Duffy 

antigen). Due to recent evidence that 

Plasmodium vivax (P. vivax) can infect 

erythroid progenitor cells (reference: YX 

Ru et al. and T Panichakul et al.), these 

cells can be potentially used for 

culturing P. vivax and other species of 

malaria. This in turn could aid 

development of malaria related 

treatments and/or products. In addition, 

the cell line can also be used for other 

hematological disease applications that 

involve red blood cells or red blood cell 

precursors. The CD36E cells also 

produce alpha, beta, and chi 

hemoglobin and therefore may be used 

for research involving hemoglobin. 

Applications: 

• Culture system for Plasmodium 

species (malaria) 

• Hematological diseases 

Advantages: Immortalized erythroid 

progenitor cell line. 

Development Status: In vitro data can 

be provided upon request. 

Market: 

• Malaria 

• Anti-malaria drug screening 

• Hematological diseases 

• Hemoglobin 

Inventors: Susan Wong, Neal S. 

Young, Ning Zhi (NHLBI). 

Relevant Publications: 

1. YX Ru et al. Invasion of 

erythroblasts by Pasmodium vivax: A 

new mechanism contributing to malarial 

anemia. Ultrastruct Pathol. 2009 

Oct;33(5):236–242. [PubMed: 

19895296]. 

2. T Panichakul et al. Production of 

erythropoietic cells in vitro for 

continuous culture of Plasmodium 

vivax. Int J Parasitol. 2007 

Dec;37(14):1551–1557. [PubMed: 

17610880]. 

Patent Status: HHS Reference No. E– 

151–2010/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

biological materials licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Heart Lung and Blood 

Institute, Hematology Branch, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize the CD36E cell line. 

Please contact Cecilia Pazman, Ph.D., at 

pazmance@mail.nih.gov for more 

information. 

Parvovirus B19 Codon Optimized 

Structural Proteins for Vaccine and 

Diagnostic Applications 

Description of Invention: Parvovirus 

B19 (B19V) is the only known 

pathogenic human parvovirus. Infection 

by this viral pathogen can cause 

transient aplastic crisis in individuals 

with high red cell turnover, pure red 

cell aplasia in immunosuppressed 

patients, and hydrops fetalis during 


emcdonald on DSK2BSOYB1PROD with NOTICES